A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer

The combination of drugs targeting Ral and PI3K/AKT signaling has antitumor efficacy in preclinical models of pancreatic cancer. We combined dinaciclib (small molecule cyclin dependent kinase inhibitor with MK‐2206 (Akt inhibitor) in patients with previously treated/metastatic pancreatic cancer. Pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Adrian G., Zahurak, Marianna, Shah, Mirat, Weekes, Colin D., Hansen, Aaron, Siu, Lillian L., Spreafico, Anna, LoConte, Noelle, Anders, Nicole M., Miles, Tearra, Rudek, Michelle A., Doyle, L. Austin, Nelkin, Barry, Maitra, Anirban, Azad, Nilofer S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719383/
https://www.ncbi.nlm.nih.gov/pubmed/32738099
http://dx.doi.org/10.1111/cts.12802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719383/
https://www.ncbi.nlm.nih.gov/pubmed/32738099
http://dx.doi.org/10.1111/cts.12802

Ejemplares similares